Therapeutics in CNS

The major central nervous system (CNS) disorders, includes brain tumors, Alzheimer’s disease, Parkinson’s disease, and stroke. These are significant threats to human health. Even though impressive advances in the treatment of CNS disorders are made during the past few decades, the success rates are still moderate if not poor. The blood–brain barrier (BBB) hampers the access of systemically administered drugs to the brain. The development of nanotechnology provides powerful tools to deliver therapeutics to target sites. Neurotransmitter pathways exist in the CNS (brain and spinal cord) just as they do in the PNS. The major excitatory neurotransmitters are the amino acids glutamate (Glu) and aspartate (Asp); the major inhibitory neurotransmitters are GABA and glycine (Gly).

 

  • Track 1-1 Nano Therapeutics
  • Track 2-2 Types of central nervous system agents
  • Track 3-3 Depressants
  • Track 4-4 Hallucinogens
  • Track 5-5 Drug effects
  • Track 6-6 Managing over dose

Related Conference of Neuroscience